Schizophrenia - future Research (Genes)
Professor David Porteous reflects upon the achievement of finding candidate genes for schizophrenia and has high hopes for the future.
Well I think what lies in store for the future is very positive. I think that we can say that because there are a number of really well confirmed findings in the field. What we are starting to see is a transition from groping in the dark, knowing there's some gold there, to having nuggets that we need now to work on. And there's much work that needs to be done. What we need to do is to work out exactly what these genes that appear to be significant risk factors do, how they affect the development of the brain, the function of the brain and the function of the individual with the outside world. It is likely that different genes will play different parts in that overall process. Some to do with early development effects, some to do with the way that different individuals handle extrasensory information and processing. There will be a variety of different contributions towards the total risk of schizophrenia. But I think perhaps the greatest hope is that we will go from a condition where we rely absolutely on signs and symptoms from clinical diagnosis towards a time when we can have a more clear-cut biological marker of the condition, as we have for example with blood cholesterol and risk of heart disease. And that's something which we really desperately need in this field to make it more objective and less subjective.
schizophrenia, candidate, genes, future, research, biological, marker, risk, factors, symptoms, diagnosis, david, porteous
Professor David Porteous discusses genes for schizophrenia and points out that susceptibility likely aligns to a combination of genetic variants.
Professor David Porteous predicts that gene medicines such as gene therapy will improve the effectiveness of treating psychiatric disorders.
A review of the causes, symptoms, and treatments of schizophrenia.
An overview of schizophrenia-related content on Genes to Cognition Online.
In this review of schizophrenia, the authors show how our growing knowledge of causal factors offers hope for successful preventive measures.
Doctor Anil Malhotra discusses emerging research relating specific genes to positive (DISC1) and negative (e.g. dysbindin) symptoms of schizophrenia.
Professor David Lewis discusses the differences between schizophrenia and bipolar disorder, noting that there here may be some shared risk factors.
Professor Daniel Weinberger discusses evidence from a number of areas of research that marks COMT as a candidate gene for schizophrenia.
Professor David Porteous describes how his group was first alerted to the DISC1 gene, which was found in a family with a pedigree of schizophrenia and psychoses.
Professor Daniel Weinberger discusses research that makes dysbindin a candidate gene for schizophrenia.